VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Older PatientsMyeloid MalignanciesConditioningHematopoietic Stem Cell Transplantation (HSCT)
Interventions
DRUG

Venetoclax (VEN)

Venetoclax (VEN) was administered at 400mg/day on days -10 to -4.

DRUG

Decitabine (DAC)

"Decitabine (DAC) was administered at 20mg/m2/day on days~-10 to -8."

DRUG

Busulfan (Bu)

"Busulfan (Bu) was administered at 3.2 mg/kg/day on days~-5 to -4."

DRUG

Fludarabine (Flu)

Fludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.

DRUG

Fludarabine (Flu)

Fludarabine (Flu) was administered at 30mg/m2/day on days -6 to -2.

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER